NIPT
Ravgen NIPT Patents Withstand Illumina Challenge
The US Patent Trial and Appeal Board delivered a pair of rulings stating that Illumina failed to show Ravgen's innovations should be considered unpatentable.
The company is planning to launch a 4-in-1 prenatal screening test, a liquid biopsy test, and a minimal residual disease assay in the coming year.
Ravgen's NIPT Patents Found Valid in Administrative Challenge
The small Maryland-based firm has launched patent lawsuits and negotiated licensing terms over technology used in market-leading noninvasive prenatal tests.
Cowen Upgrades PerkinElmer Stock to Outperform
Analyst Max Masucci said the firm is expected to generate at least $3.21 billion in COVID-19-related revenues, while he lowered the stock price target to $164 per share.
Juno Diagnostics Lowers Barriers to Noninvasive Prenatal Testing With At-Home Sample Collection
Premium
The Hazel assay uses finger prick amounts of blood, from which it immediately separates plasma that can be shipped at room temperature for chromosomal analysis.